With the past one week's decline, the stock of the pharmaceutical company has corrected 59 per cent from its record high level of Rs 742 touched on August 17, 2021.
In Q4, Hikal’s consolidated profit after tax (PAT) declined 59 per cent year on year (YoY) to Rs 21 crore, due to higher operational cost and lower revenue. The company had posted a PAT of Rs 51 crore in the year-ago quarter. Earnings before interest, taxes, depreciation, and amortization (EBITDA) contracted by 834 bps to 12.15 per cent from 20.49 per cent in Q4FY21.
The company’s revenue was down 5.6 per cent to Rs 502 crore from Rs 532 crore last year. The pharmaceutical segment recorded muted 3 per cent YoY revenue growth at Rs 308 crore due to demand softening and lower off-take by the customers. The crop protection segment de-grew by 17 per cent YoY to Rs 194 crore.
The muted revenue growth in pharmaceutical business was in line with the recent trend witnessed by the API industry due to strong transient headwinds of softening demand and disruptions in global supply chains. This combined with the challenging raw material disruptions and significant increase in input costs has seen a pressure on margins in Q4, which the management expects to continue through the first half of the year.
"As the industry faces strong headwinds due to the inflationary pressures and a sharp rise in input costs of raw material, energy and solvents, we expect growth to be tapered and margins to be contract in the current fiscal", the management said.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app